Lomecel-B medicinal signaling cells
Phase 2Active 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypoplastic Left Heart Syndrome
Conditions
Hypoplastic Left Heart Syndrome
Trial Timeline
Jun 25, 2021 → Aug 31, 2026
NCT ID
NCT04925024About Lomecel-B medicinal signaling cells
Lomecel-B medicinal signaling cells is a phase 2 stage product being developed by Longeveron for Hypoplastic Left Heart Syndrome. The current trial status is active. This product is registered under clinical trial identifier NCT04925024. Target conditions include Hypoplastic Left Heart Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04925024 | Phase 2 | Active |
Competing Products
1 competing product in Hypoplastic Left Heart Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Allo-hMSCs + Placebo | Longeveron | Phase 1 | 25 |
Other Products from Longeveron
Allogeneic MSCPhase 2
44
Longeveron Mesenchymal Stem Cells (LMSCs)Phase 2
44
Peripheral Intravenous (IV) infusion of LMSCsPhase 2
44
Longeveron Mesenchymal Stem CellsPhase 1/2
33
Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs) + Placebo + Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)Phase 1/2
33